Cardiovascular and Metabolic Disease segment
The Cardiovascular and Metabolic Disease (or CVMD segment) is the largest contributor of revenues for AstraZeneca (AZN). The CVMD segment contributed nearly 35.2% to the company’s total revenues in 2016, following a strong performance of Brilinta, Farxiga, Seloken, and Bydureon. This upswing was offset by lower sales of Onglyza, Byetta, Crestor, and Atacand.
Brilinta, a growth platform product, is used to prevent blood clots in heart and blood vessels. The drug’s 2016 revenues reported a 39% operational increase to $839 million.
Brilinta’s sales rose 45% to $348 million, with an ~14% increase in its European markets sales to $258 million and an ~80% increase in its sales for emerging markets to $189 million at constant exchange rates.
Farxiga is used to treat type 2 diabetes in adults. It reported revenues of $835 million during 2016, a 72% growth in revenues at constant exchange rates. This includes 75% growth in sales in the US, 96% growth in sales in emerging markets, and 52% growth in sales in European markets.
Onglyza, a diabetes product to control blood sugar levels, reported revenues of $720 million during 2016, a 6% decrease in revenues at constant exchange rates. This includes a 10% decrease in sales in the US markets, 4% decrease in sales in the emerging markets and 5% decrease in the European markets.
Used to reduce cholesterol and triglycerides in the blood, Crestor contributed ~14.8% to AstraZeneca’s total 2016 revenues. At constant exchange rates, Crestor’s revenues fell 32% to $3.4 billion during 2016. In the US markets, the revenues fell 57% to ~$1.2 billion following the drug’s patent expiry in May 2016.
Outside the drug’s US markets, its Europe markets reported revenues of $866 million, a 4% decline due to competition from generic statins. Sales in emerging markets increased during 2016.
Other CVMD products
Other products in this segment include Bydureon, Byetta, and Seloken. Bydureon’s revenues were flat at $578 million in 2016, while Byetta’s sales fell 19% to $254 million during 2016.